Published in J Clin Invest on December 01, 2010
Inhibition of thrombotic properties of persistent autoimmune anti-β2GPI antibodies in the mouse model of antiphospholipid syndrome. Blood (2013) 1.45
ApoE Receptor 2 Mediation of Trophoblast Dysfunction and Pregnancy Complications Induced by Antiphospholipid Antibodies in Mice. Arthritis Rheumatol (2016) 1.44
Endothelium--role in regulation of coagulation and inflammation. Semin Immunopathol (2011) 1.37
Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome. J Neural Transm (Vienna) (2013) 1.20
A novel pathway for human endothelial cell activation by antiphospholipid/anti-β2 glycoprotein I antibodies. Blood (2011) 1.07
The cholesterol metabolite 27-hydroxycholesterol promotes atherosclerosis via proinflammatory processes mediated by estrogen receptor alpha. Cell Metab (2014) 1.01
Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS. Blood (2014) 0.99
Apelin/APJ signaling is a critical regulator of statin effects in vascular endothelial cells--brief report. Arterioscler Thromb Vasc Biol (2012) 0.88
Genetic variants of ApoE and ApoER2 differentially modulate endothelial function. Proc Natl Acad Sci U S A (2014) 0.85
Anti-β2GPI antibodies stimulate endothelial cell microparticle release via a nonmuscle myosin II motor protein-dependent pathway. Blood (2013) 0.85
Antiphospholipid antibodies attenuate endothelial repair and promote neointima formation in mice. J Am Heart Assoc (2014) 0.84
New Insights into the Molecular Basis of the Antiphospholipid Syndrome. Drug Discov Today Dis Mech (2011) 0.81
Apolipoprotein E receptor-2 deficiency enhances macrophage susceptibility to lipid accumulation and cell death to augment atherosclerotic plaque progression and necrosis. Biochim Biophys Acta (2014) 0.79
A Subregion of Reelin Suppresses Lipoprotein-Induced Cholesterol Accumulation in Macrophages. PLoS One (2015) 0.78
H(2)S inhibits oscillatory shear stress-induced monocyte binding to endothelial cells via nitric oxide production. Mol Cells (2012) 0.78
A novel TRPV4-specific agonist inhibits monocyte adhesion and atherosclerosis. Oncotarget (2016) 0.77
An A1-A1 mutant with improved binding and inhibition of β2GPI/antibody complexes in antiphospholipid syndrome. FEBS J (2015) 0.76
Inhibition of nitric oxide and antiphospholipid antibody-mediated thrombosis. Curr Rheumatol Rep (2013) 0.76
Connective tissue diseases: blockade of NO production drives thrombosis in APS. Nat Rev Rheumatol (2011) 0.75
Identification of a Monoclonal Antibody That Attenuates Antiphospholipid Syndrome-Related Pregnancy Complications and Thrombosis. PLoS One (2016) 0.75
Identification of the binding site for fondaparinux on Beta2-glycoprotein I. Biochim Biophys Acta (2013) 0.75
Loss of Reelin protects against atherosclerosis by reducing leukocyte-endothelial cell adhesion and lesion macrophage accumulation. Sci Signal (2016) 0.75
Recent advances in understanding antiphospholipid syndrome. F1000Res (2016) 0.75
The Utility of Ovotransferrin and Ovotransferrin-Derived Peptides as Possible Candidates in the Clinical Treatment of Cardiovascular Diseases. Oxid Med Cell Longev (2017) 0.75
Circulating anti-beta2-glycoprotein I antibodies are associated with endothelial dysfunction, inflammation, and high nitrite plasma levels in patients with intermittent claudication. Int J Inflam (2013) 0.75
Prevalence of anti- beta2GPI antibodies and their isotypes in patients with renal diseases and clinical suspicion of antiphospholipid syndrome. J Nephropathol (2013) 0.75
Soluble analog of ApoER2 targeting beta2-glycoprotein I in immune complexes counteracts hypertension in lupus-prone mice with spontaneous antiphospholipid syndrome. J Thromb Haemost (2016) 0.75
Activated signature of antiphospholipid syndrome neutrophils reveals potential therapeutic target. JCI Insight (2017) 0.75
Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers. Curr Rheumatol Rep (2017) 0.75
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost (2006) 16.11
Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet (1990) 6.54
Reeler/Disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2. Cell (1999) 5.52
Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A (1990) 4.59
The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun (1987) 3.25
39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. J Biol Chem (1991) 3.17
Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet (1990) 2.87
Regulation of endothelial nitric oxide synthase: location, location, location. Annu Rev Physiol (2002) 2.79
Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough? J Pharmacol Exp Ther (2001) 2.74
Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J Biol Chem (2001) 2.56
Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest (2003) 2.39
Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med (2002) 2.09
FcgammaRIIB mediates C-reactive protein inhibition of endothelial NO synthase. Circ Res (2005) 1.97
Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med (2004) 1.95
Signal transduction of eNOS activation. Cardiovasc Res (1999) 1.92
Leukocyte-endothelial cell interactions in nitric oxide synthase-deficient mice. Am J Physiol (1999) 1.72
Interaction of beta2-glycoprotein I with members of the low density lipoprotein receptor family. J Thromb Haemost (2006) 1.59
Anticardiolipin IgG subclasses: association of IgG2 with arterial and/or venous thrombosis. Arthritis Rheum (1997) 1.52
Regulation of platelet granule exocytosis by S-nitrosylation. Proc Natl Acad Sci U S A (2005) 1.52
Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice. Clin Cancer Res (2005) 1.50
Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. Arthritis Rheum (1997) 1.45
Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood (2005) 1.44
Deficient platelet-derived nitric oxide and enhanced hemostasis in mice lacking the NOSIII gene. Circ Res (1999) 1.41
Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood (2003) 1.37
Elimination of cholesterol in macrophages and endothelial cells by the sterol 27-hydroxylase mechanism. Comparison with high density lipoprotein-mediated reverse cholesterol transport. J Biol Chem (1997) 1.36
Molecular cloning and sequence analysis of the catalytic subunit of bovine type 2A protein phosphatase. Proc Natl Acad Sci U S A (1987) 1.32
The complement system in the pathophysiology of pregnancy. Mol Immunol (2006) 1.30
Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost (2008) 1.29
Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood (2005) 1.29
The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost (2009) 1.28
Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest (1997) 1.28
Site-specific dephosphorylation of endothelial nitric oxide synthase by protein phosphatase 2A: evidence for crosstalk between phosphorylation sites. Biochemistry (2002) 1.27
Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment. Proc Natl Acad Sci U S A (2004) 1.26
The scavenger receptor class B type I adaptor protein PDZK1 maintains endothelial monolayer integrity. Circ Res (2008) 1.25
Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A (1998) 1.24
beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood (2004) 1.23
IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood (2004) 1.19
Platelet activation by dimeric beta2-glycoprotein I requires signaling via both glycoprotein Ibalpha and apolipoprotein E receptor 2'. J Thromb Haemost (2008) 1.18
Radiation-enhanced vascular targeting of human lung cancers in mice with a monoclonal antibody that binds anionic phospholipids. Clin Cancer Res (2007) 1.16
Platelet adhesion to dimeric beta-glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein Ibalpha and apolipoprotein E receptor 2'. J Thromb Haemost (2006) 1.14
Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res (2001) 1.11
Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol (2002) 1.08
Nitric oxide insufficiency and atherothrombosis. Histochem Cell Biol (2004) 1.08
Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation (1992) 1.07
Impaired platelet production of nitric oxide predicts presence of acute coronary syndromes. Circulation (1998) 1.07
Annexin A5 as a novel player in prevention of atherothrombosis in SLE and in the general population. Ann N Y Acad Sci (2007) 1.07
Platelets express three different splice variants of ApoER2 that are all involved in signaling. J Thromb Haemost (2007) 1.05
Glutamate mediates platelet activation through the AMPA receptor. J Exp Med (2008) 1.04
Neuronal nitric oxide synthase (NOS) regulates leukocyte-endothelial cell interactions in endothelial NOS deficient mice. Br J Pharmacol (2001) 1.04
Arterial disease and thrombosis in the antiphospholipid syndrome: a pathogenic role for endothelin 1. Arthritis Rheum (1998) 1.04
Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood (2006) 1.02
Relationship between anti-phospholipid and anti-endothelial cell antibodies III: beta 2 glycoprotein I mediates the antibody binding to endothelial membranes and induces the expression of adhesion molecules. Clin Exp Rheumatol (1995) 1.02
Identification of a novel exon in apolipoprotein E receptor 2 leading to alternatively spliced mRNAs found in cells of the vascular wall but not in neuronal tissue. J Biol Chem (2001) 1.01
Endothelial cell activation by antiphospholipid antibodies. Clin Immunol (2004) 1.00
Monoclonal antibodies from NZW x BXSB F1 mice to beta2 glycoprotein I and cardiolipin. Species specificity and charge-dependent binding. J Immunol (1996) 1.00
Embryonic vasculogenesis by endothelial precursor cells derived from lung mesenchyme. Dev Dyn (2000) 0.97
Toll-like receptors: another player in the pathogenesis of the anti-phospholipid syndrome. Lupus (2008) 0.96
Role of infectious agents in systemic rheumatic diseases. Clin Exp Rheumatol (2008) 0.96
Apolipoprotein E (apoE) isoforms differentially induce nitric oxide production in endothelial cells. FEBS Lett (2003) 0.95
Inflammatory response and the endothelium. Thromb Res (2004) 0.94
The binding site in {beta}2-glycoprotein I for ApoER2' on platelets is located in domain V. J Biol Chem (2005) 0.92
Annexin A2: biology and relevance to the antiphospholipid syndrome. Lupus (2008) 0.92
Antiphospholipid antibodies activate vascular endothelial cells. Lupus (1996) 0.90
Exocytosis of endothelial cells is regulated by N-ethylmaleimide-sensitive factor. Methods Mol Biol (2008) 0.89
Association between beta2-glycoprotein I plasma levels and the risk of myocardial infarction in older men. Blood (2009) 0.88
In vitro model for developmental progression from vasculogenesis to angiogenesis with a murine endothelial precursor cell line, MFLM-4. Microvasc Res (2001) 0.86
Complement activation: a novel pathogenic mechanism in the antiphospholipid syndrome. Ann N Y Acad Sci (2005) 0.86
Tissue factor in the antiphospholipid syndrome. Lupus (2008) 0.83
Neutrophil activation by anti-beta 2 glycoprotein I monoclonal antibodies via Fc gamma receptor II. J Leukoc Biol (1995) 0.83
Endothelial function is impaired in patients with primary antiphospholipid syndrome. Thromb Res (2005) 0.82
The role of antiphospholipid syndrome in cardiovascular disease. Hematol Oncol Clin North Am (2008) 0.81
Beta2-glycoprotein I and LDL-receptor family members. Thromb Res (2004) 0.80
Is there a microangiopathic antiphospholipid syndrome? Ann Rheum Dis (2007) 0.79
Impaired brachial endothelial function in patients with primary anti-phospholipid syndrome. Int J Clin Pract (2004) 0.78
Primary antiphospholipid antibody syndrome with mutations in the phospholipid binding domain of beta(2)-glycoprotein I. Am J Hematol (2000) 0.78
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst (2005) 13.00
HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med (2014) 8.61
Suppression of aging in mice by the hormone Klotho. Science (2005) 8.11
Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med (2003) 7.86
Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum (2002) 5.12
Nitric oxide regulates exocytosis by S-nitrosylation of N-ethylmaleimide-sensitive factor. Cell (2003) 4.55
Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Science (2002) 4.15
LRP: role in vascular wall integrity and protection from atherosclerosis. Science (2003) 3.89
Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study. Ann Intern Med (2015) 3.63
Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers? Trends Mol Med (2004) 3.44
Prolonged fluid shear stress induces a distinct set of endothelial cell genes, most specifically lung Krüppel-like factor (KLF2). Blood (2002) 3.38
Modulation of synaptic plasticity and memory by Reelin involves differential splicing of the lipoprotein receptor Apoer2. Neuron (2005) 3.25
Smooth muscle-selective deletion of guanylyl cyclase-A prevents the acute but not chronic effects of ANP on blood pressure. Proc Natl Acad Sci U S A (2002) 3.03
Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J Clin Invest (2009) 2.89
Identification of neuronal RNA targets of TDP-43-containing ribonucleoprotein complexes. J Biol Chem (2010) 2.72
Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med (2006) 2.68
Endothelial and antithrombotic actions of HDL. Circ Res (2006) 2.68
Reelin and ApoE receptors cooperate to enhance hippocampal synaptic plasticity and learning. J Biol Chem (2002) 2.67
Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron (2007) 2.55
Endothelin-1 induces alveolar epithelial-mesenchymal transition through endothelin type A receptor-mediated production of TGF-beta1. Am J Respir Cell Mol Biol (2007) 2.50
Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta. Science (2002) 2.45
Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene (2002) 2.41
TDP-43 is a developmentally regulated protein essential for early embryonic development. J Biol Chem (2009) 2.40
Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest (2003) 2.39
Complement activation fragment Bb in early pregnancy and spontaneous preterm birth. Am J Obstet Gynecol (2008) 2.38
Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol (2009) 2.37
Independent association of rheumatoid arthritis with increased left ventricular mass but not with reduced ejection fraction. Arthritis Rheum (2009) 2.33
Reelin activates SRC family tyrosine kinases in neurons. Curr Biol (2003) 2.29
Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res (2002) 2.21
27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat Med (2007) 2.18
Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy. Circulation (2014) 2.16
Regulation of Weibel-Palade body exocytosis. Trends Cardiovasc Med (2005) 2.16
Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med (2006) 2.16
Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med (2002) 2.09
Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood (2010) 2.04
Pros and cons for C4d as a biomarker. Kidney Int (2012) 2.03
Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med (2012) 2.01
Sex ratios among children of lupus pregnancies. Arthritis Rheum (2013) 1.98
FcgammaRIIB mediates C-reactive protein inhibition of endothelial NO synthase. Circ Res (2005) 1.97
Estrogen modulation of endothelial nitric oxide synthase. Endocr Rev (2002) 1.97
Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med (2004) 1.95
High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J Biol Chem (2003) 1.92
β-radiation reduces the reactivity of extracellular matrix proteins in intravascular brachytherapy (IVBT), resulting in decreased platelet adhesion. Int J Cardiol (2010) 1.91
Non-nuclear estrogen receptor alpha signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. J Clin Invest (2010) 1.90
Skin blood flow influences near-infrared spectroscopy-derived measurements of tissue oxygenation during heat stress. J Appl Physiol (1985) (2005) 1.90
Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: rational therapeutic approach to frontotemporal dementia. J Biol Chem (2011) 1.88
Reelin-mediated signaling locally regulates protein kinase B/Akt and glycogen synthase kinase 3beta. J Biol Chem (2002) 1.88
Proteolytic processing of low density lipoprotein receptor-related protein mediates regulated release of its intracellular domain. J Biol Chem (2002) 1.83
C-reactive protein downregulates endothelial NO synthase and attenuates reendothelialization in vivo in mice. Circ Res (2007) 1.82
Reactive oxygen species impair sympathetic vasoregulation in skeletal muscle in angiotensin II-dependent hypertension. Hypertension (2006) 1.82
Neuronal LRP1 functionally associates with postsynaptic proteins and is required for normal motor function in mice. Mol Cell Biol (2004) 1.81
A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol Cancer Res (2004) 1.79
A novel class of fusion polypeptides inhibits exocytosis. Mol Pharmacol (2004) 1.78
Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nat Genet (2003) 1.77
High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I. Circ Res (2005) 1.77
iRHOM2 is a critical pathogenic mediator of inflammatory arthritis. J Clin Invest (2013) 1.77
β₂-glycoprotein I: a novel component of innate immunity. Blood (2011) 1.75
27-hydroxycholesterol is an endogenous selective estrogen receptor modulator. Mol Endocrinol (2007) 1.75
Estrogen causes dynamic alterations in endothelial estrogen receptor expression. Circ Res (2002) 1.74
Platelet-derived growth factor mediates tyrosine phosphorylation of the cytoplasmic domain of the low Density lipoprotein receptor-related protein in caveolae. J Biol Chem (2002) 1.74
ERbeta has nongenomic action in caveolae. Mol Endocrinol (2002) 1.73
Adipocyte LDL receptor-related protein-1 expression modulates postprandial lipid transport and glucose homeostasis in mice. J Clin Invest (2007) 1.73
Genetic linkage and association of Fcgamma receptor IIIA (CD16A) on chromosome 1q23 with human systemic lupus erythematosus. Arthritis Rheum (2002) 1.71
Molecular imaging of activated von Willebrand factor to detect high-risk atherosclerotic phenotype. JACC Cardiovasc Imaging (2010) 1.71
Nitric oxide-dependent modulation of sympathetic neural control of oxygenation in exercising human skeletal muscle. J Physiol (2002) 1.70
Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo. PLoS One (2009) 1.67
A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol Immunol (2005) 1.67
Receptor clustering is involved in Reelin signaling. Mol Cell Biol (2004) 1.66
Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum (2012) 1.66
Endocytic receptor LRP together with tPA and PAI-1 coordinates Mac-1-dependent macrophage migration. EMBO J (2006) 1.66
Reelin modulates NMDA receptor activity in cortical neurons. J Neurosci (2005) 1.65
TDP-43 is directed to stress granules by sorbitol, a novel physiological osmotic and oxidative stressor. Mol Cell Biol (2010) 1.64
Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nat Med (2008) 1.64
Identification of coagulation factor XI as a ligand for platelet apolipoprotein E receptor 2 (ApoER2). Arterioscler Thromb Vasc Biol (2009) 1.64
Phosphatidylinositol 3-kinase interacts with the adaptor protein Dab1 in response to Reelin signaling and is required for normal cortical lamination. J Biol Chem (2003) 1.63
Factor VIII half-life and clinical phenotype of severe hemophilia A. Haematologica (2005) 1.63
Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy. Int J Radiat Oncol Biol Phys (2002) 1.62
Cholesterol binding, efflux, and a PDZ-interacting domain of scavenger receptor-BI mediate HDL-initiated signaling. J Clin Invest (2005) 1.62
End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol (2014) 1.62
Interferon-α and angiogenic dysregulation in pregnant lupus patients who develop preeclampsia. Arthritis Rheumatol (2015) 1.61
Lrp4 modulates extracellular integration of cell signaling pathways in development. PLoS One (2008) 1.60
The glycoprotein Ib-IX-V complex contributes to tissue factor-independent thrombin generation by recombinant factor VIIa on the activated platelet surface. Blood (2008) 1.59